Drug and Financial Stocks Under Pressure as Wall Street Stalls
US stock prices closed lower today, as drug and financial shares sent both the S&P 500 and the Dow Jones Industrial Average to their first consecutive sessions of declines in more than a month.
Tuesday, March 7, 2017 - 00:00
The Dow Jones Industrial Average fell 29.58 points, or 0.14 percent, to 20,924.76, the S&P 500 lost 6.92 points, or 0.29 percent, to 2,368.39 and the Nasdaq Composite dropped 15.25 points, or 0.26 percent, to 5,833.93.
Pharmaceutical stocks came under pressure after US. President Donald Trump tweeted he was working on a "new system" to reduce drug prices in the industry, without providing details. Trump also backed a draft bill unveiled by Republicans on Monday to repeal and replace the Obamacare healthcare law, but said the bill was open to negotiation.
Newly minted shares of Snapchat owner Snap Inc plunged 9.8 percent to $21.44 after analysts gave the company a lukewarm reception following its red-hot market debut, attracting short-sellers.
Investors were also preparing for the likelihood of an interest rate hike when the US Federal Reserve meets next week. A number of key officials, including Chair Janet Yellen, have made comments indicating a hike is likely at its March 14-15 meeting.
US.Treasury yields rose, supporting the dollar, as investors made room for this week's supply of government debt and also in anticipation of a Fed rate hike later this month. The monthly US. jobs report, due on Friday, is expected to show an increase of 190,000 jobs, probably enough to push the Fed to raise its base rate again for the second time in four months.
The market seems to be taking in stride expectations the Fed will raise rates, unlike past years,
This information has been prepared by Nadex, a trading name of North American Derivatives Exchange, Inc., prepared by independent third parties contracted by Nadex or reproduced form third party news agencies. In addition to the disclaimer below, the material on this page does not contain an offer of, or solicitation for, a transaction in any financial instrument. Nadex accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.